Navigation Links
Vermillion Announces $21.8 Million Public Offering
Date:2/15/2011

ectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.  

This release should be read in conju
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vermillion Receives Award From the Society of Gynecologic Oncologists
2. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
3. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
4. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
5. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
6. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
7. Vermillion Announces the Reappointment of Officers and Confirmation of Director
8. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
9. Vermillion Announces $43.05 Million Private Placement of Common Stock
10. Vermillion Files Plan of Reorganization
11. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... The Bill & Melinda Gates Foundation today announced that Dr. ... Health Program. Mundel, who is currently global head of development ... will start work at the foundation on December 1. ... to lead our global health program," said Bill Gates, co-chair ...
... Kan., Sept. 13, 2011 Bayer HealthCare LLC, Animal ... treatment system at its U.S. headquarters in Shawnee, Kan. ... one million gallons of water, or the equivalent of ... proprietary wastewater system began in early 2010 by CDI ...
Cached Medicine Technology:Gates Foundation Names Dr. Trevor Mundel to Lead Global Health Program 2Bayer Conserves One Million Gallons of Water through Wastewater Treatment Process at Shawnee Headquarters 2Bayer Conserves One Million Gallons of Water through Wastewater Treatment Process at Shawnee Headquarters 3Bayer Conserves One Million Gallons of Water through Wastewater Treatment Process at Shawnee Headquarters 4
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
(Date:4/22/2014)... LAKE CITY)A computational tool developed at the University of ... unknown gene mutations in three separate cases, U of ... study in The American Journal of Human Genetics ... tool), identifies undiagnosed illnesses and unknown gene mutations by ... that code for genes are made, in individual patients ...
(Date:4/22/2014)... cell lung cancer are 70 years of age or ... are not well represented in clinical trials. Therefore, the ... reach evidence based clinical recommendations. , In 2010, the ... Cancer Group along with the International Society for Geriatric ... for elderly patients with non-small cell lung cancer (NSCLC), ...
(Date:4/22/2014)... exposed to trauma, illness, alcohol or other drug abuse, ... brain cells that can go awry and activate conditions ... of autism. , Until now, it has been unclear ... a developing brain. Past studies have shown that when ... abuse or she experiences some trauma or illness, her ...
(Date:4/22/2014)... 2014) Cedars-Sinai stroke intervention researchers have been informed ... part of the National Institutes of Health, will award ... II clinical trial of an experimental drug for stroke. ... combination with recombinant tissue plasminogen activator, or rtPA ... shortly after onset. In laboratory rodent studies, 3K3A-APC, used ...
Breaking Medicine News(10 mins):Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3
... November 2, 2009 (Downey, Calif.) Aggressively managing patients at ... the United States by 25 percent, according to a Kaiser ... Journal of Bone & Joint Surgery . The first step ... osteoporosis disease management, researchers say. This study, the largest ...
... screening in high-risk study patients , MONDAY, Nov. 2 ... at high risk for lung cancer, researchers say. , ... people in Colorado who were seeing their primary care ... complete a five-minute questionnaire that collected information about lung ...
... SINGAPORE, Nov. 2 /PRNewswire-Asia/ -- GfK ... information in line with the,17th Hong Kong Optical Fair, hosted ... in October 2009 include China, Hong Kong, Korea,Singapore and Malaysia. ... be better or the same in 2010. , ...
... athletes, who wear helmets in their careers, to help erase ... YORK, Nov. 2 November is Epilepsy Awareness Month. The ... American Epilepsy Outreach Foundation (AEOF) has joined with ... Annual Helmets for Hope(TM) Campaign. The Helmets for Hope(TM) is ...
... Preliminary evaluation after completion of treatment ... has been met for patients with advanced-stage, ... 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: ... focused on endocrine therapy and oncology, today announced positive ...
... ... is expanding operations in the U.S. Martel provides custom printer solutions for products such ... equipment. Martel,s customers in the U.S. include Abbott Laboratories. , ... (PRWEB) November 2, 2009 -- Martel ...
Cached Medicine News:Health News:Nation's hip fracture rate could drop 25 percent with aggressive osteoporosis prevention 2Health News:Nation's hip fracture rate could drop 25 percent with aggressive osteoporosis prevention 3Health News:Asian Optical Retailers Upbeat about 2010 2Health News:Asian Optical Retailers Upbeat about 2010 3Health News:Helmets for Hope Campaign and Gala 2Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 2Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 3Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 4Health News:Martel Instruments Expands Its Custom Printer Solutions Business in North America; Liz Peirce Named Director of North American Business Development 2
...
...
The Lineage acetabular system with metal liners uses sophisticated manufacturing methods and materials to minimize wear debris generation....
The Pivot Bipolar was designed with a simple one-step assembly interface between the femoral head and the compression molded liner which requires no instruments and reduces OR time....
Medicine Products: